176 related articles for article (PubMed ID: 34276352)
1. Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
He H; Wu W; Zhang Y; Zhang M; Sun N; Zhao L; Wang X
Front Pharmacol; 2021; 12():586827. PubMed ID: 34276352
[No Abstract] [Full Text] [Related]
2. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
4. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.
Gao W; Yu B; Yan Y; Zhao L; Zhao R
Front Immunol; 2023; 14():1151977. PubMed ID: 37304299
[TBL] [Abstract][Full Text] [Related]
5. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.
Golhen K; Winskill C; Theiler M; Buettcher M; Yeh YH; Zhang N; Welzel T; Pfister M
Front Med (Lausanne); 2022; 9():944208. PubMed ID: 36226155
[TBL] [Abstract][Full Text] [Related]
6. Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis.
Choi S; Oh S; Yoon HS
Ann Dermatol; 2022 Jun; 34(3):173-181. PubMed ID: 35721333
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
[TBL] [Abstract][Full Text] [Related]
8. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G; Zangrilli A; Bernardini N; Bavetta M; De Simone C; Graceffa D; Bonifati C; Faleri S; Giordano D; Mariani M; Micheli A; Moretta G; Pagnanelli G; Panasiti V; Provini A; Richetta A; Peris K; Bianchi L
Dermatol Ther; 2022 Jun; 35(6):e15489. PubMed ID: 35385202
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.
Demirel Öğüt N; Koç Yıldırım S; Erbağcı E; Hapa FA
J Cosmet Dermatol; 2022 Nov; 21(11):6215-6224. PubMed ID: 35801372
[TBL] [Abstract][Full Text] [Related]
10. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
11. Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Ambikaibalan D; Quaade AS; Halling AS; Thyssen JP; Egeberg A
Dermatology; 2021; 237(2):158-165. PubMed ID: 32894834
[TBL] [Abstract][Full Text] [Related]
12. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.
Lebwohl MG; Soliman AM; Yang H; Wang J; Hagan K; Padilla B; Pinter A
Dermatol Ther (Heidelb); 2022 Feb; 12(2):407-418. PubMed ID: 34921669
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes.
Egeberg A; Merola JF; Schäkel K; Puig L; Mahar PD; Wang IY; Pavo I; Schuster C; Griffiths CEM
Front Med (Lausanne); 2022; 9():1092688. PubMed ID: 36777159
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
[TBL] [Abstract][Full Text] [Related]
18. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
19. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
